Close Menu

Inscripta

Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.

Researchers in academia and industry are showing interest in the scale offered by Inscripta's Onyx platform for genome editing, launched in October.

The company said it will use the funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform.

Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.

Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs. 

The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.

The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.

In Genome Research this week: mutational signature linked to acrylamide exposure, computational platform for identifying viral integrations in cancer, and more.

CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.

The company, which had raised $55.5 million in February, said its investors have agreed to contribute an additional $30 million.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.